CClinicalTrials.gg
CompletedNCT02005588Updated Jul 28, 2015

Treatment of Iron Deficiency Anemia With Pregnancy

An Early Phase 1 interventional study of amino acid chelated iron and iron salt (ferrous fumarate) in Iron Deficiency Anemia of Pregnancy, sponsored by Cairo University. Completed at 1 site in Egypt. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2015-07-28.

Sponsored by Cairo University · Early Phase 1, Interventional, and Treatment

Phase
Early Phase 1
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

Iron deficiency anemia is a very common problem accompanying pregnancy. in this study, the investigators are going to compare the efficacy and tolerability of two preparations of oral iron in treatment of iron deficiency anemia with pregnancy.

Read the detailed description

In this study, the investigators are going to compare two preparations of oral iron in treatment of iron deficiency anemia with pregnancy. a total of 300 pregnant women will be randomly divided into two equal groups (each containing 150 pregnant woman). one group will receive amino acid chelated iron and the other group will receive iron salt (ferrous fumarate). All pregnant women attending the obstetrics outpatient clinic of kasr al aini hospital at 14-18 weeks gestation will be submitted to complete blood picture and serum ferritin. those who prove to have iron deficiency anemia (hemoglobin less than 11g/dl and serum ferritin less than 12ug/l) will be included in the study. All eligible women will be followed up at 22-23, 29-30 and 36-37 weeks' gestation for the change in hemoglobin level and ferritin level. all women will be also enquired about different side effects during treatment period.

02

Conditions studied

  • Iron Deficiency Anemia of Pregnancy

Keywords

  • amino acid chelated iron
  • iron salt
  • iron deficiency anemia
03

In context

Anemia

1,733 studies on the registry are indexed under Anemia; 246 are open to participants now.

This study's enrollment of 150 is above the median of 94 across 1,291 interventional studies indexed under Anemia.

Browse Anemia studies →

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Age: 20-40 years
  • Pregnant 14-18 weeks
  • Singleton fetus
  • Hb 7-10.9 g/dl
  • Serum ferritin \<12 microgram/L

Exclusion criteria

Exclusion Criteria:

  • history of anemia due to other causes as chronic blood loss, hemolytic anemia or thalassemia
  • Multiple pregnancy
  • known hepatic, renal or cardiovascular abnormality.
  • Known peptic ulcer, esophagitis, gastritis or hiatus hernia.
  • Family history of thalassemia, sickle cell anemia, or malabsorption syndrome.
  • Iron preparation intake within 24 hours of inclusion
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Active comparator
    amino acid chelated iron arm

    this arm will contain 150 pregnant women with proved iron deficiency anemia and pregnant 14-18 weeks. these pregnant women will be given amino acid chelated iron capsules (15 mg iron/capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules, and hemoglobin 9.1-11 g/dl will receive 1 capsule). complete blood picture and serum ferritin will be assessed at 22-23 weeks, 29-30 weeks and 36-37 weeks. possible side effects (colicky abdominal pains, constipation and metallic taste) will be asked about in each follow up visit.

    Drug: amino acid chelated iron · Drug: iron salt (ferrous fumarate)

  • Active comparator
    iron salt arm

    this arm will contain 150 pregnant women with proved iron deficiency anemia and 14-18 weeks gestation. these women will be given oral iron salt ferrous fumarate capsules (350 mg iron/ capsule containing about 70 mg elemental iron/ capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules daily and hemoglobin 9.1-11 g/dl will receive 1 capsule daily. women will be followed up with complete blood picture and serum ferritin at 22-23 weeks, 29-30 weeks and 36-37 weeks. women will be asked about possible side effects (colicky abdominal pains, constipation, and metallic taste) in each visit.

    Drug: amino acid chelated iron · Drug: iron salt (ferrous fumarate)

Interventions

  • Drugamino acid chelated iron

    the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.

    Also known as: ferrotron capsules

  • Drugiron salt (ferrous fumarate)

    this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.

    Also known as: hemoton capsules

06

What researchers measure

Primary outcomes

  1. change in hemoglobin level

    Time frame: 6 months

Secondary outcomes

  1. the occurence of side effects (abdominal colics, constipation, or metallic taste)

    Time frame: 6 months

  2. change in serum ferritin level

    Time frame: 6 months

Other outcomes

  1. cost of treatment

    Time frame: 6 months

07

Study locations

1 site
  • faculty of medicine, Cairo University
    Cairo, 002, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02005588
Lead sponsor
Cairo University
Responsible party
Ghada Abdel Fattah (lecturer of obstetrics and gynecology, faculty of medicine, Cairo University, Cairo University) — Principal investigator
First posted
Dec 9, 2013
Start date
Dec 2013
Primary completion
Jun 2015
Completion
Jul 2015
Last update
Jul 28, 2015

Study contacts

Ahmed M Sayed, professor
study director · Cairo University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion